Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SKY 0515

Next Previous
Drug Profile

SKY 0515

Alternative Names: SKY-0515

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Skyhawk Therapeutics
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action RNA splicing modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Huntington's disease

Most Recent Events

  • 18 Jun 2025 Phase-II/III clinical trials in Huntington's disease in New Zealand and Australia (PO) (NCT06873334)
  • 18 Jun 2025 Skyhawk Therapeutics completes enrollment in phase I clinical trials in Huntington's disease (In volunteers) in Australia (PO) (ACTRN12623001161617)
  • 10 Jul 2024 Skyhawk Therapeutics plans a phase II/III trial for Huntington’s disease in May 2025 (NCT06873334)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top